Skip to main content
MedPathMedPath Home
Clinical Trials/NCT01331902
NCT01331902
Unknown
Phase 4

Comparison of Hyperemic Efficacy Between Nicorandil and Adenosine for Fractional Flow Reserve (FFR) Measurement

Seoul National University Hospital1 site in 1 country200 target enrollmentMarch 2011
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCoronary Artery DiseaseMyocardial Ischemia

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Coronary Artery Disease
Sponsor
Seoul National University Hospital
Enrollment
200
Locations
1
Primary Endpoint
Fractional Flow Reserve at Maximal Hyperemia
Last Updated
15 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

The purpose of this study is to evaluate the efficacy of nicorandil in the achievement of maximal coronary hyperemia compared with adenosine.

Registry
clinicaltrials.gov
Start Date
March 2011
End Date
September 2011
Last Updated
15 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •non -infarct related, patients with moderate coronary artery stenosis
  • •normal left ventricular ejection fraction on echocardiogram

Exclusion Criteria

  • •infarct-related arteries or clinically unstable state
  • •collateral blood flow to the target vessel is shown
  • •atrioventricular block on electrocardiogram
  • •reduced left ventricular ejection fraction (\<50%) or left ventricular hypertrophy on echocardiogram
  • •contraindication of adenosine
  • •bronchial asthma

Outcomes

Primary Outcomes

Fractional Flow Reserve at Maximal Hyperemia

Time Frame: 1 day

Secondary Outcomes

  • Time to Maximal Hyperemia(1 day)
  • Changes in Heart Rate(1 day)

Study Sites (1)

Loading locations...

Similar Trials

Unknown
Phase 4
Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina.Chronic Stable Angina
NCT01397994Ferozsons Laboratories Ltd.40
Completed
Not Applicable
Hyperemic Efficacy of nicorandil for fractional flow reserve measurement in patients with stable coronary artery diseaseischemic heart disease
JPRN-UMIN000019309Chiba University Graduate School of Medicine50
Completed
Not Applicable
Comparative bioequivalence study of the Nicorandil 20-mg tablets manufactured by Modava Pharmaceoutical company
IRCT20130313012810N6Modava Pharmaceutical Company24
Recruiting
Phase 3
Effect of Nicorandil on contrast-induced nephropathycontrast-induced nephropathy.Nephropathy induced by other drugs, medicaments and biological substancesICD 10- N1
IRCT20230110057096N1Rasht University of Medical Sciences264
Unknown
Phase 2
Comparative Study Between Nicorandil and Nifedipine for the Treatment of Preterm LabourPreterm Labor With Preterm Delivery
NCT04846621Ain Shams University230